Eltrombopag/Eltrombopag has significant efficacy, but you need to be wary of side effects

Eltrombopag (Eltrombopag), an oral, non-peptide thrombopoietin receptor agonist, has demonstrated unique efficacy in the treatment of chronic immune thrombocytopenia (ITP). It activates the thrombopoietin signaling pathway and stimulates the bone marrow to produce normal platelets, thereby effectively increasing platelet levels in patients. Studies have pointed out that eltrombopag interacts with the TPO-R transmembrane domain during megakaryocytopoiesis, further promoting platelet production and significantly reducing the incidence of bleeding events.

For patients with thrombocytopenia, the effect of eltrombopag is not only to increase platelet count. More importantly, it can significantly improve patients' bleeding symptoms, such as common nosebleeds, gum bleeding, and skin purpura. As platelet levels improve and bleeding symptoms ease, patients' quality of life improves significantly, allowing them to cope with daily activities with greater ease.

The use of eltrombopag is not without risks. Some patients may experience gastrointestinal discomfort, such as nausea, vomiting, abdominal pain, and diarrhea after taking eltrombopag. In addition, allergic reactions are also one of the common side effects of eltrombopag. Patients may experience allergic symptoms such as rash, itching, redness and swelling. What's more serious is that long-term use of eltrombopag may inhibit the hematopoietic function of the bone marrow, leading to adverse reactions such as leukopenia and anemia. Of particular concern is that eltrombopag may increase the risk of bleeding in patients, especially those with a preexisting bleeding tendency.

Therefore, when using eltrombopag, patients should strictly follow the doctor's instructions, take it on time and in the right amount, and pay close attention to their own adverse reactions. If you experience severe discomfort or suspected side effects, you should seek professional help immediately.